An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily.

Trial Profile

An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2015

At a glance

  • Drugs Digoxin; Fostamatinib
  • Indications Arrhythmias; B cell lymphoma; Chronic lymphocytic leukaemia; Immune thrombocytopenic purpura; Ischaemic heart disorders; Rheumatoid arthritis; Solid tumours; T cell lymphoma; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Oct 2015 Results published in the Clinical Therapeutics
    • 05 Oct 2011 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
    • 05 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top